Hydroxychloroquine in Lupus Pregnancy: What Do We Know?

Abstract

Pregnancy is of significant concern for systemic lupus erythematosus (SLE) patients of childbearing age because SLE is associated with increased maternal and fetal morbidity. Therapeutic options utilizing antimalarials, most notably hydroxychloroquine (HCQ) and other immunosuppressants, such as azathioprine and tacrolimus, are compatible with pregnancy. HCQ is the first-line treatment in SLE pregnancy, and its use has been recommended throughout pregnancy to control active SLE activity. In this review, we summarize up to date knowledge on the benefits and therapeutic utilities of HCQ in lupus pregnancy.

Clin Infect Immun. 2022;7(2):31-36
doi: https://doi.org/10.14740/cii155